Hi @bavarian1975, have you bought in?
Business looks like it is about to pick up big time this quarter for both IRX 211 and IRX 616a. I posted this on their separate threads.
First patient first dose for IRX 211 phase 2 trial could follow soon now that batch manufacturing has begun.
IRX 616a is due to start its phase 1 and a stack of news is expected.
It does appear the company is in a catalyst-rich quarter, but I think the more important thing is we have this favorable funding to bring both trials right to the doorstep of phase 3 trials. There's a bunch of clinical stage small cap companies with the cup out getting pounded into the ground whereas we've been bucking the trend.
The company feels on the cusp of a sentiment shift and a market rerate.
Add to My Watchlist
What is My Watchlist?
